

## AMANTADINE ER

#### Gocovri, Osmolex ER (amantadine ER)

## Pre - PA Allowance

None

# **Prior-Approval Requirements**

Age 18 years of age or older

#### Diagnoses

Patient must have **ONE** of the following:

#### Gocovri

- 1. Parkinson's disease (PD)
  - a. Patient is experiencing dyskinesia
  - b. Currently receiving levodopa-based therapy
  - c. Prescribing physician has attempted to adjust levodopa therapy to decrease dyskinesia

## **Osmolex ER**

- 1. Parkinson's disease (PD)
- 2. Drug-induced EPS (extrapyramidal symptoms)

#### AND ALL of the following for ALL drugs:

- 1. Documented baseline evaluation of the patient's symptoms
- 2. Inadequate treatment response, intolerance, or contraindication to other adjunctive therapy
- 3. Inadequate treatment response or intolerance to short acting amantadine
- 4. NO end-stage renal disease (ESRD)

#### Gocovri ONLY

Age 18 years of age or older

#### Diagnosis

Patient must have the following:

- 1. Parkinson's disease (PD) experiencing "off" episodes
  - a. Used in combination with levodopa/carbidopa
  - b. Inadequate control of Parkinson's symptoms on maximum tolerated doses of oral levodopa/carbidopa



AMANTADINE ER

Gocovri, Osmolex ER (amantadine ER)

c. NO end-stage renal disease (ESRD)

# **Prior - Approval Limits**

Gocovri

Quantity

Strength	Quantity
68.5 mg	180 capsules per 90 days OR
137 mg	180 capsules per 90 days

Maximum daily limit of any combination: 274 mg

OR

## Osmolex ER

#### Quantity

Strength	Quantity
129 mg	90 tablets per 90 days OR
193 mg	90 tablets per 90 days OR
258 mg	90 tablets per 90 days OR
322 mg dosing kit	180 tablets per 90 days
(129 mg + 193 mg)	

Maximum daily limit of any combination: 322 mg

**Duration** 12 months

# Prior – Approval Renewal Requirements

Age 18 years of age or older

#### Diagnoses

Patient must have **ONE** of the following:

#### Gocovri

- 1. Parkinson's disease (PD)
  - a. Patient is experiencing dyskinesia
  - b. Currently receiving levodopa-based therapy

## **Osmolex ER**



Federal Employee Program.

## AMANTADINE ER

## Gocovri, Osmolex ER (amantadine ER)

- 1. Parkinson's disease (PD)
- 2. Drug-induced EPS (extrapyramidal symptoms)

## AND ALL of the following for ALL drugs:

- 1. Documented improvement in symptoms from baseline
- 2. NO end-stage renal disease (ESRD)

## Gocovri ONLY

Age 18 years of age or older

## Diagnosis

Patient must have the following:

- 1. Parkinson's disease (PD) experiencing "off" episodes
  - a. Used in combination with levodopa/carbidopa
  - b. Improvement in Parkinson's symptoms
  - c. NO end-stage renal disease (ESRD)

## **Prior – Approval Renewal Limits**

Same as above